DDrare: Database of Drug Development for Rare Diseases

58. 肥大型心筋症
［臨床試験数：92，薬物数：126（DrugBank：35），標的遺伝子数：40，標的パスウェイ数：141］

Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE; 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride; Acetylcysteine; Adenosine; Air; Alcohol; Antiarrhythmic drugs; Atorvastatin; BNP; BNP blood sample test; Behavioral: Lifestyle; Bluefish; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CK-3773274; CK-3773274 (10 - 30 mg); CK-3773274 (5 - 15 mg); CK-3773274 - Granules in Capsule; CK-3773274 - Tablets; CT-G20; Candesartan; Carnitine; Cufence; Cyclosporine; Cyclosporine A; Device: Insertable cardiac monitor; Device: Magnetic resonance imaging (MRI) with gadolinium enhancement; Device: Magnetic resonance imaging (MRI) without gadolinium enhancement; Device: Use of bioanalytical assay to monitor plasma levels of perhexiline; Diagnostic Test: Air venous plethysmography; Diagnostic Test: Echocardiography; Diagnostic Test: Electrocardiogram; Diagnostic Test: Exercise Stress Transthoracic Echocardiogram; Diagnostic Test: Holter ECG; Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy; Diagnostic Test: Upper member arterial Doppler echography with analysis of FMD; Diltiazem; Diovan; Diovan 160 mg; Diovan 40 mg; Diovan 80 mg; Dobutamine; Echo and myocardial contrast echocardiography perfusion imaging; Eleclazine; Endothelial function biomarkers; Entresto; GS-6615 3 mg; GS-6615 3 mg Pink; GS-6615 3 mg White; GS-6615 6 mg; GS-6615 6 mg White; Gadolinium; Gradient; Gutron 2,5mg; Gutron 5mg; Hyperpolarized 13C-Pyruvate; LCZ696; LCZ696 100 mg; LCZ696 200 mg; LCZ696 50 mg; Losartan; Losartan Bluefish 50 mg; MAVACAMTEN; MEK162; MIDODRINE HYDROCHLORIDE; MONITOR; MYK-461; Mangafodipir; Mavacamten; Metoprolol; Metoprolol Succinate; Midodrine; N-acetylcysteine; Nitrate; Other: Exercise echocardiography; Other: Mangafodipir trisodium; Other: Walk distance test; Perhexiline; Perxexiline; Pexsig; Phosphorous; Piperazine; Pirfenidone; Procedure: 3D electrocardiographic mapping (ECM); Procedure: B-lines SE; Procedure: Coronary flow reserve SE; Procedure: Diastolic function SE; Procedure: Echocardiography (TEE); Procedure: Left ventricular contractile reserve SE; Procedure: Left ventricular outflow tract gradient SE; Procedure: Mitral regurgitation SE; Procedure: Pulmonary hemodynamics SE; Procedure: RF catheter ablation; Procedure: trans-right ventricular alcohol septal ablation (TRVASA); Pyrazole; RANEXA; RANEXA*60CPR 500MG R.P.; RANEXA*60CPR 750MG R.P.; RANOLAZINE; Ranexa; Ranolazine; Ranolazine 1000 mg PR tablets; Ranolazine 500 mg PR tablets; Ranolazine 750 mg PR tablets; Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die; Regadenoson; SACUBITRIL VALSARTAN; Sacubitril; Sacubitril/Valsartan; Sacubitril/valsartan; Sodium Nitrate; Sodium nitrate; Spironolactone; Treatment BX1514M; Trientine; Trientine Dihydrochloride; Trientine dihydrochloride; Triethylinetetramine dihydrochloride; Trimetazidine; Trimetazidine Dihydrochloride 20mg; Trimetazidine dihydrochloride; VALSARTAN; Valsartan; Vastarel; Vastarel 20mg film coated tablets; [MYK-461]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04426578 (ClinicalTrials.gov)	August 1, 2020	14/5/2020	Role of Perhexiline in Hypertrophic Cardiomyopathy	Randomised Controlled Trial of pErhexiline on regreSsion Of Left Ventricular hypErtrophy (LVH) in Patients With Symptomatic Hypertrophic CardioMyopathy (RESOLVE-HCM)	Hypertrophic Cardiomyopathy	Drug: Perhexiline;Other: Placebo	Flinders University	NULL	Not yet recruiting	18 Years	N/A	All	60	Phase 2	NULL
2	NCT02862600 (ClinicalTrials.gov)	August 1, 2016	8/8/2016	Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure	A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function	Cardiomyopathy, Hypertrophic;Cardiomyopathy, Hypertrophic, Familial	Drug: Perhexiline;Device: Use of bioanalytical assay to monitor plasma levels of perhexiline	Heart Metabolics Limited	NULL	Terminated	18 Years	N/A	All	35	Phase 2	United States
3	NCT02431221 (ClinicalTrials.gov)	July 22, 2015	27/4/2015	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure	A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure	Hypertrophic Cardiomyopathy	Drug: Perhexiline;Drug: Placebo	Heart Metabolics Limited	NULL	Withdrawn	18 Years	N/A	All	0	Phase 3	NULL
4	NCT00500552 (ClinicalTrials.gov)	December 2006	10/7/2007	Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy	Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)	Hypertrophic Cardiomyopathy	Drug: Perhexiline/Placebo	University Hospital Birmingham	British Heart Foundation;University College London Hospitals;University of Oxford	Completed	18 Years	80 Years	Both	44	Phase 2	United Kingdom
5	EUCTR2005-000755-15-GB (EUCTR)	25/10/2005	27/05/2005	Perhexiline therapy in patients with Hypertrophic Cardiomyopathy	Perhexiline therapy in patients with Hypertrophic Cardiomyopathy	Hypertrophic Cardiomyopathy	Product Name: Pexsig INN or Proposed INN: Perxexiline	University Hospital of Birmingham Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50		United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04426578
(ClinicalTrials.gov)

August 1, 2020

14/5/2020

Role of Perhexiline in Hypertrophic Cardiomyopathy

Randomised Controlled Trial of pErhexiline on regreSsion Of Left Ventricular hypErtrophy (LVH) in Patients With Symptomatic Hypertrophic CardioMyopathy (RESOLVE-HCM)

Hypertrophic Cardiomyopathy

Drug: Perhexiline;Other: Placebo

Flinders University

NULL

Not yet recruiting

18 Years

N/A

All

Phase 2

NULL

NCT02862600
(ClinicalTrials.gov)

August 1, 2016

8/8/2016

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function

Cardiomyopathy, Hypertrophic;Cardiomyopathy, Hypertrophic, Familial

Drug: Perhexiline;Device: Use of bioanalytical assay to monitor plasma levels of perhexiline

Heart Metabolics Limited

NULL

Terminated

18 Years

N/A

All

Phase 2

United States

NCT02431221
(ClinicalTrials.gov)

July 22, 2015

27/4/2015

Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure

A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure

Hypertrophic Cardiomyopathy

Drug: Perhexiline;Drug: Placebo

Heart Metabolics Limited

NULL

Withdrawn

18 Years

N/A

All

Phase 3

NULL

NCT00500552
(ClinicalTrials.gov)

December 2006

10/7/2007

Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy

Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)

Hypertrophic Cardiomyopathy

Drug: Perhexiline/Placebo

University Hospital Birmingham

British Heart Foundation;University College London Hospitals;University of Oxford

Completed

18 Years

80 Years

Both

Phase 2

United Kingdom

EUCTR2005-000755-15-GB
(EUCTR)

25/10/2005

27/05/2005

Perhexiline therapy in patients with Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Product Name: Pexsig
INN or Proposed INN: Perxexiline

University Hospital of Birmingham Foundation Trust

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

United Kingdom